EUCTR2020-001211-24-FR进行中（未招募）1 期
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS - Not Applicable
Dermira Inc. a wholly-owned subsidiary of Eli Lilly and Company0 个研究点目标入组 900 人开始时间: 2021年5月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Received treatment in a Dermira-sponsored lebrikizumab study, DRM06-AD04, DRM06-AD05, DRM06-AD06, DRM06-AD17 or DRM06-AD18 (parent trial) and have adequately completed the study treatments and last patient visit of the parent trial.
- •2. Willing and able to comply with all clinic visits and study-related procedures.
- •3. For women of childbearing potential: agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least 18 weeks after the last dose of lebrikizumab or placebo.
- •NOTE: A woman of childbearing potential (WOCBP) is defined as a postmenarcheal female, who has not reached a postmenopausal state (= 12 continuous months of amenorrhea with no identified cause other than menopause) and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- •NOTE: The following are highly effective contraceptive methods: combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) associated with inhibition of ovulation, progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, or sexual abstinence. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- •4. Male patients must agree to use an effective barrier method of contraception during the study and for a minimum of 18 weeks following the last dose of study drug if sexually active with a female of child-bearing potential.
- •5. Provide signed informed consent/assent as described in Section 10.2.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 100
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 700
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1. Patients who, during their participation in the parent trial, developed a serious adverse event (SAE) deemed related to lebrikizumab, which in the opinion of the investigator or Study Protocol: DRM06-AD07 Lebrikizumab of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the patient.
- •2. Patients who, during their participation in the parent trial, developed an AE that was deemed related to lebrikizumab and led to study treatment discontinuation, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the patient.
- •3. Conditions in the previous parent study consistent with protocol-defined criteria for permanent study drug discontinuation, if deemed related to lebrikizumab or led to investigator - or sponsor-initiated withdrawal of patient from the study (e.g., noncompliance, inability to complete study assessments, etc.).
- •4. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
- •* Note for exclusion criteria # 1, 2, and 3: In studies that are still blinded, conditions deemed related to the study treatment will be considered related to lebrikizumab.
研究者
相似试验
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2020-001211-24-LVDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisAtopic dermatitisEUCTR2020-001211-24-DEDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2020-001211-24-LTDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2020-001211-24-ESDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900
进行中（未招募）
1 期
A long-term study to assess the safety and efficacy of Lebrikizumabin patients with moderate –to-Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2020-001211-24-EEDermira Inc. a wholly-owned subsidiary of Eli Lilly and Company900